New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
08:42 EDTMNKDMannKind Afrezza facing 'daunting' commercial hurdles, says JPMorgan
JPMorgan believes Afrezza's label with a Black Box warning and requirement for pulmonary testing show the FDA's concerns around pulmonary toxicity. The firm believes the drug faces "daunting" commercial hurdles and it keeps a Neutral rating on the stock with a $6 price target.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:47 EDTMNKDMannKind's Afrezza lags behind in inhaled insulin market, The Street reports
The number of prescriptions written for MannKind's (MNKD) Afrezza is lagging behind in the diabetes market, reports The Street. This comes five months after Sanofi (SNY) launched the product. Afrezza is also under-performing Exubera, the first inhaled insulin launched by Pfizer (PFE) nine years ago. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use